New Data from Biogen's Investigational Antisense Oligonucleo

In the Phase 1b study, favorable trends were reported for the high-dose groups on multiple measures of cognition and function.First study of a tau targeting drug that shows reduction of aggregated tau...

Related Keywords

United States , Boston , Massachusetts , Cambridge , Cambridgeshire , United Kingdom , America , Jack Cox , Priya Singhal , Chuck Triano , Asia Pacific , Brightfocus Foundation , Youtube , Linkedin , Head Of Development At Biogen , Alzheimer Association , Exchange Commission , Facebook , Nasdaq , Biogen Inc , International Conference On Alzheimer , Clinical Dementia Rating Sum , Mini Mental State Exam , Functional Activities Questionnaire , International Conference , North America , Safe Harbor , Tau Protein , Accessed September , From Discovery , Tau Topic , Accessed October , Markets ,